Genflow Biosciences (LSE:GENF) ROCE % : -164.81% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Genflow Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genflow Biosciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -164.81%.

Genflow Biosciences ROCE % Historical Data

The historical data trend for Genflow Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genflow Biosciences ROCE % Chart

Genflow Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-1,764.29

-110.24

-105.37

Genflow Biosciences Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-64.97	-105.78	-42.88	-60.82	-164.81

Genflow Biosciences ROCE % Calculation

Genflow Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.629	/	( ( (2.617 - 0.251)	+	(1.072 - 0.346) )	/ 2 )
	=	-1.629	/	( (2.366	+	0.726)	/ 2 )
	=	-1.629	/	1.546
	=	-105.37 %

Genflow Biosciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-2.014	/	( ( (1.912 - 0.194)	+	(1.072 - 0.346) )	/ 2 )
	=	-2.014	/	( ( 1.718	+	0.726 )	/ 2 )
	=	-2.014	/	1.222
	=	-164.81 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Genflow Biosciences (LSE:GENF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genflow Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Genflow Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genflow Biosciences (LSE:GENF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genflow Biosciences PLC (LSE:GENF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

WQ5:Germany

Address

6 Heddon Street, London, GBR, W1B 4BT

Website

https://www.genflowbio.com

Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.

Genflow Biosciences (LSE:GENF) Headlines

No Headlines